692 completed, 101 unknown, 74 terminated, 28 withdrawn. 227 Phase 2, 201 Phase 3, 144 Phase 4, 105 Phase 1, 55 Not applicable.
Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer PIVKA-II and GAAD score calculation - Liver Cirrhosis, Hepatitis B, Chronic | Not applicable | Enrolling by invitation | Siriraj Hospital | 2100 | 2026-02-02 | 2026-04-24 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
| Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia Does not apply - Hepatitis C Virus Infection | Unknown | Asociación Colombiana de Hepatología | 205 | 2024-05-20 | 2024-06-18 | |
| Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina. standard of care - Hepatitis C Chronic, Hepatitis C | Unknown | Hospital El Cruce | 800 | 2024-05-01 | 2024-04-18 | |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative. Meridan Bioscience Point of Care test against HCV antibodies - Hepatitis C, Chronic, Hepatitis C | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 4000 | 2023-04-10 | 2023-04-14 | |
| Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually - Carcinoma, Hepatocellular, Hepatitis C, Chronic | Recruiting | Ruijin Hospital | 20000 | 2023-03-01 | 2023-05-23 | |
| The Efficacy of Vosevi in Treating DAA-experienced Patients Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C, Medication Reaction | Recruiting | The Third Affiliated Hospital of Guangzhou Medical University | 200 | 2023-02-28 | 2024-03-13 | |
| A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs Incentive payment - Hepatitis C, Chronic | Not applicable | Unknown | Kirby Institute | 400 | 2022-10-01 | 2022-04-14 |
| Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera sofosbuvir and daclatasvir - Hepatitis C, Chronic | Early Phase 1 | Unknown | Assiut University | 40 | 2022-10-01 | 2022-07-26 |
| Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs Xpert HCV Viral Load Fingerstick, Aptima HCV Quant DX Assay - Hepatitis C, Hepatitis C, Chronic | Not applicable | Completed | Kirby Institute | 1801 | 2022-07-27 | 2026-06-03 |
| Linkage to Care for Persons With Hep C Infection Peer specialist (PS), Incentives, telehealth visits - Hepatitis C, Chronic, Substance Use Disorders | Not applicable | Completed | Carilion Clinic | 60 | 2022-07-12 | 2026-07-07 |
| Possible Differences in HCC Course Depending on DAA Treatment Direct Acting Antivirals - Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of | Unknown | Medical University of Warsaw | 100 | 2022-05-10 | 2022-05-17 | |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs HCV RNA (PCR), HCV Antibody test (Point of care), AST/ALT and platelets measurement - Hepatitis C, Chronic | Completed | Queen Mary University of London | 25000 | 2021-11-01 | 2026-07-17 | |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir - Chronic Hepatitis C, Chronic Hepatitis B | Phase 4 | Unknown | Peking University First Hospital | 120 | 2021-08-01 | 2021-08-09 |
| Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs) HIV Infection, Hepatitis C | Completed | Johns Hopkins University | 828 | 2021-03-31 | 2022-02-21 | |
| Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals Hepatitis C, Chronic | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 321 | 2021-03-01 | 2021-11-17 | |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
Showing 20 of 907. Sign in to see all of them.
Hepatitis C (318) · Fibrosis (41) · Hepatitis (35) · Liver Diseases (34) · Liver Cirrhosis (28) · Acquired Immunodeficiency Syndrome (22) · HIV Infections (20) · Virus Diseases (18) · Hepatitis, Chronic (16) · Carcinoma, Hepatocellular (14) · Hepatitis B, Chronic (13) · Hepatitis, Viral, Human (12) · Infections (12) · Insulin Resistance (9)
Blood-Borne Infections (907) · Chronic Disease (907) · Disease Attributes (907) · Pathologic Processes (907) · Pathological Conditions, Signs and Symptoms (907) · Communicable Diseases (906) · Digestive System Diseases (900) · Flaviviridae Infections (899) · RNA Virus Infections (898) · Hepatitis, Viral, Human (895) · Infections (895) · Hepatitis, Chronic (891) · Virus Diseases (889) · Liver Diseases (873) · Hepatitis (872)
Ribavirin (399) · peginterferon alfa-2a (202) · peginterferon alfa-2b (112) · Sofosbuvir (57) · ombitasvir (43) · paritaprevir (39) · dasabuvir (36) · daclatasvir (33) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (30) · telaprevir (29) · Simeprevir (27) · Ritonavir (26) · glecaprevir and pibrentasvir (24) · ledipasvir, sofosbuvir drug combination (23) · glecaprevir (21)
Merck Sharp & Dohme LLC (107) · Hoffmann-La Roche (82) · AbbVie (71) · Gilead Sciences (34) · Boehringer Ingelheim (18) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (17) · Bristol-Myers Squibb (15) · National Taiwan University Hospital (12) · French National Agency for Research on AIDS and Viral Hepatitis (11) · Kirby Institute (11) · Tanabe Pharma Corporation (11) · ANRS, Emerging Infectious Diseases (10) · Kaohsiung Medical University Chung-Ho Memorial Hospital (10) · Vertex Pharmaceuticals Incorporated (10) · AbbVie (prior sponsor, Abbott) (9)
United States (245) · France (107) · Germany (93) · Spain (81) · Canada (77) · Puerto Rico (71) · Australia (62) · United Kingdom (61) · Italy (52) · Taiwan (49) · Poland (48) · Belgium (45) · Austria (41) · Egypt (41) · China (35)
Chen-Hua Liu, MD (8) · Fumitaka Suzuki, MD (5) · Ming-Lung Yu, MD, PhD (5)
PMID 30739368, PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 30529905, PMID 29377566, PMID 30868245, PMID 28193518, PMID 23607593, PMID 24329937, PMID 25040192, PMID 26947564, PMID 27553375, PMID 29404492, PMID 29461687, PMID 35174470, PMID 37096802, PMID 12823087, PMID 20189674, PMID 22626609, PMID 23300053, PMID 23607594, PMID 24126097, PMID 24154738, PMID 24209977, PMID 24428467, PMID 25196718, PMID 25583164, PMID 25777337, PMID 26158171, PMID 26173631, PMID 26321288, PMID 26596948, PMID 26733671, PMID 26867206, PMID 26936417, PMID 27920566, PMID 28412293, PMID 28480293, PMID 29180522, PMID 29909549, PMID 30552056, PMID 31376493, PMID 32682494, PMID 34307188, PMID 11413125, PMID 12450640, PMID 12618532, PMID 15282352
2014 (16), 2015 (14), 2009 (9), 2004 (7), 2005 (7), 2008 (7), 2016 (6), 2019 (2), R01DA013806 (2), R01DA026727 (2), K23DA022454 (1), K23DK089004 (1), K24DK066144 (1), R01DA016065 (1), R01DA034086 (1)